Barium
- Generic Name
- Barium
- Drug Type
- Small Molecule
- Chemical Formula
- Ba
- CAS Number
- 7440-39-3
- Unique Ingredient Identifier
- 24GP945V5T
- Background
Barium is under investigation for the diagnostic of Known or Suspected Abdominal Disease.
Physiological Study of the Human CYP3A Activity (PiSA)
Phase 4
Completed
- Conditions
- Cytochrome P450 CYP3A Enzyme Deficiency
- Interventions
- Drug: AB (Midazolam OD formulation/Dormicum)
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 12
- Registration Number
- NCT03204578
- Locations
- 🇨ðŸ‡
University Hospital Basel,, Basel, Basel Stadt, Switzerland
Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy
Not Applicable
Active, not recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Barium SwallowBehavioral: QuestionnairesBehavioral: Neurocognitive ExamsDevice: Expiratory Muscle Strength Training (EMST) DeviceDevice: Digital Manometer
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 175
- Registration Number
- NCT02662907
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Uniformity of Oral Contrast Material in the Bowel
Completed
- Conditions
- Known or Suspected Abdominal Disease
- Interventions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 900
- Registration Number
- NCT02542046
- Locations
- 🇺🇸
UCSF, San Francisco, California, United States
Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo inhalation powder
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT02172352
Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)
Phase 1
Withdrawn
- Conditions
- Dysplastic Nevus Syndrome
- Interventions
- Drug: 20% betulinic acid ointment
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- University of Illinois at Chicago
- Registration Number
- NCT00346502
- Locations
- 🇺🇸
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 157
- Registration Number
- NCT00292448
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yokote, Akita, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath